BACKGROUND: While it is well established that the cell-mediated immune response plays an important role in cancer progression and spread, the role of the humoral immune response in this regard has been less studied. According to the existing literature, dense infiltration of B cells or plasma cells appears to correlate mainly with an improved prognosis in several types of cancer, but their prognostic impact in oesophageal and gastric cancer has not yet been described. METHODS: Immunohistochemistry was applied on tissue microarrays (TMA) to assess the stromal density of B cells (CD20+) and plasma cells [CD138+ or immunoglobulin kappa C (IGKC+)] in chemo-/radiotherapy-naive tumours from a consecutive cohort of 174 patients with resected oesophageal or gastric adenocarcinoma. Cox proportional hazard's modelling was applied to examine the impact of the investigated markers on overall survival (OS) and time to recurrence (TTR). RESULTS: In curatively treated patients with oesophageal adenocarcinoma, high expression of IGKC was an independent predictor of a prolonged OS [hazard ratio (HR) 0.10; 95% confidence interval (CI), 0.02-0.57], and TTR (HR 0.15; 95% CI, 0.03-0.71). In curatively treated patients with gastric adenocarcinoma, high expression of IGKC independently predicted a prolonged OS (HR 0.46; 95% CI, 0.24-0.87) and TTR (HR 0.46; 95% CI, 0.21-0.98). Expression of CD20 was not prognostic, and CD138 expression was only prognostic in unadjusted analysis of TTR in gastric cancer. CONCLUSIONS: These results demonstrate, for the first time, that abundant infiltration of IGKC+ plasma cells independently predicts a prolonged survival in both oesophageal and gastric cancer.
BACKGROUND: While it is well established that the cell-mediated immune response plays an important role in cancer progression and spread, the role of the humoral immune response in this regard has been less studied. According to the existing literature, dense infiltration of B cells or plasma cells appears to correlate mainly with an improved prognosis in several types of cancer, but their prognostic impact in oesophageal and gastric cancer has not yet been described. METHODS: Immunohistochemistry was applied on tissue microarrays (TMA) to assess the stromal density of B cells (CD20+) and plasma cells [CD138+ or immunoglobulin kappa C (IGKC+)] in chemo-/radiotherapy-naive tumours from a consecutive cohort of 174 patients with resected oesophageal or gastric adenocarcinoma. Cox proportional hazard's modelling was applied to examine the impact of the investigated markers on overall survival (OS) and time to recurrence (TTR). RESULTS: In curatively treated patients with oesophageal adenocarcinoma, high expression of IGKC was an independent predictor of a prolonged OS [hazard ratio (HR) 0.10; 95% confidence interval (CI), 0.02-0.57], and TTR (HR 0.15; 95% CI, 0.03-0.71). In curatively treated patients with gastric adenocarcinoma, high expression of IGKC independently predicted a prolonged OS (HR 0.46; 95% CI, 0.24-0.87) and TTR (HR 0.46; 95% CI, 0.21-0.98). Expression of CD20 was not prognostic, and CD138 expression was only prognostic in unadjusted analysis of TTR in gastric cancer. CONCLUSIONS: These results demonstrate, for the first time, that abundant infiltration of IGKC+ plasma cells independently predicts a prolonged survival in both oesophageal and gastric cancer.
Authors: Marcus Schmidt; Daniel Böhm; Christian von Törne; Eric Steiner; Alexander Puhl; Henryk Pilch; Hans-Anton Lehr; Jan G Hengstler; Heinz Kölbl; Mathias Gehrmann Journal: Cancer Res Date: 2008-07-01 Impact factor: 12.701
Authors: Maria C Svensson; Carl Fredrik Warfvinge; Richard Fristedt; Charlotta Hedner; David Borg; Jakob Eberhard; Patrick Micke; Björn Nodin; Karin Leandersson; Karin Jirström Journal: Oncotarget Date: 2017-07-21
Authors: Sarah Spear; Juliana B Candido; Jacqueline R McDermott; Cristina Ghirelli; Eleni Maniati; Stephen A Beers; Frances R Balkwill; Hemant M Kocher; Melania Capasso Journal: Front Immunol Date: 2019-03-27 Impact factor: 7.561
Authors: Sangwoo S Kim; Whitney A Sumner; Sayuri Miyauchi; Ezra E W Cohen; Joseph A Califano; Andrew B Sharabi Journal: Clin Cancer Res Date: 2021-07-06 Impact factor: 12.531
Authors: David Borg; Anna H Larsson; Charlotta Hedner; Björn Nodin; Anders Johnsson; Karin Jirström Journal: J Transl Med Date: 2018-10-24 Impact factor: 5.531
Authors: Elin Sjöberg; Magnus Frödin; John Lövrot; Artur Mezheyeuski; Martin Johansson; Ulrika Harmenberg; Lars Egevad; Per Sandström; Arne Östman Journal: Br J Cancer Date: 2018-10-08 Impact factor: 7.640
Authors: Martin Jeremiasen; David Borg; Charlotta Hedner; Maria Svensson; Björn Nodin; Karin Leandersson; Jan Johansson; Karin Jirström Journal: Front Oncol Date: 2020-10-23 Impact factor: 6.244